The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis

A systematic review and meta-analysis examining the association between anti-merozoite antibody responses and incidence of Plasmodium falciparum malaria by Freya Fowkes and colleagues aids identification of antigens that confer protection from malaria.

[1]  D. Moher,et al.  Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews , 1996, The Lancet.

[2]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[3]  R. Coppel,et al.  Naturally Acquired Antibody Responses to Plasmodium falciparum Merozoite Surface Protein 4 in a Population Living in an Area of Endemicity in Vietnam , 2001, Infection and Immunity.

[4]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[5]  D. Conway,et al.  Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria , 2008, Infection and Immunity.

[6]  A. Cowman,et al.  Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies. , 2008, The Journal of clinical investigation.

[7]  A. Sabchareon,et al.  Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes , 1990, The Journal of experimental medicine.

[8]  C. Rogier,et al.  Long-Term Clinical Protection from Falciparum Malaria Is Strongly Associated with IgG3 Antibodies to Merozoite Surface Protein 3 , 2007, PLoS medicine.

[9]  D. Conway,et al.  Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria , 2003, Parasite immunology.

[10]  K. Marsh,et al.  Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum , 2008, PloS one.

[11]  George Davey Smith,et al.  Meta-analysis: Principles and procedures , 1997, BMJ.

[12]  K. Marsh,et al.  Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure , 2009, Infection and Immunity.

[13]  A. Cowman,et al.  Invasion of Red Blood Cells by Malaria Parasites , 2006, Cell.

[14]  D. Conway,et al.  Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. , 2004, Vaccine.

[15]  R. Anders,et al.  Specificity of the Protective Antibody Response to Apical Membrane Antigen 1 , 2001, Infection and Immunity.

[16]  R. Steele,et al.  Plasmodium falciparum malaria. , 1999, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.

[17]  A. Holder,et al.  Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia , 2004, Infection and Immunity.

[18]  L. Miller,et al.  Parasite ligand-host receptor interactions during invasion of erythrocytes by Plasmodium merozoites. , 2004, International journal for parasitology.

[19]  R. Chilengi,et al.  Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children , 2008, Malaria Journal.

[20]  R. Anders,et al.  Target antigens of purified human immunoglobulins which inhibit growth of Plasmodium falciparum in vitro , 1982, Nature.

[21]  D. Conway,et al.  High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. , 2006, Vaccine.

[22]  A. Holder,et al.  Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.

[23]  A. Cowman,et al.  Antibodies against Merozoite Surface Protein (Msp)-119 Are a Major Component of the Invasion-Inhibitory Response in Individuals Immune to Malaria , 2001, The Journal of experimental medicine.

[24]  D. Conway,et al.  A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses , 2000, Nature Medicine.

[25]  T. Smith,et al.  Attributable fraction estimates and case definitions for malaria in endemic areas. , 1994, Statistics in medicine.

[26]  E. Riley,et al.  Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children , 1993, Infection and immunity.

[27]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[28]  O. Doumbo,et al.  A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections , 1993, Infection and immunity.

[29]  B. Greenwood,et al.  IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. , 1998, The American journal of tropical medicine and hygiene.

[30]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[31]  P. Gilson,et al.  Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness , 2009, Infection and Immunity.

[32]  Andrea Crisanti,et al.  Profiling the antibody immune response against blood stage malaria vaccine candidates. , 2007, Clinical chemistry.

[33]  A. Holder,et al.  Human antibodies to the 19 kDa C‐terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro , 1999, Parasite immunology.

[34]  I. McGregor,et al.  Gamma-Globulin and Acquired Immunity to Human Malaria , 1961, Nature.

[35]  Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  M. Kieny,et al.  Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults , 2008, PloS one.

[37]  M. Theisen,et al.  Natural antibody response to Plasmodium falciparum Exp‐1, MSP‐3 and GLURP long synthetic peptides and association with protection , 2004, Parasite immunology.

[38]  L. Marrama,et al.  Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. , 2005, Journal of Infectious Diseases.

[39]  D. Conway,et al.  Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3 , 2007, Parasite immunology.

[40]  T. Theander,et al.  Levels of Antibody to Conserved Parts of Plasmodium falciparum Merozoite Surface Protein 1 in Ghanaian Children Are Not Associated with Protection from Clinical Malaria , 1999, Infection and Immunity.

[41]  D. Conway,et al.  Antibodies to the N-Terminal Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Associated with Protection against Clinical Malaria , 2004, Infection and Immunity.

[42]  A. Fleming.  Opportunistic infections in AIDS in developed and developing countries. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[43]  G. Butcher,et al.  Action of Malarial Antibody in vitro , 1969, Nature.

[44]  L. Marrama,et al.  Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure. , 2003, The Journal of infectious diseases.

[45]  C. John,et al.  Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa1 , 2004, The Journal of Immunology.

[46]  J. Aponte,et al.  A country-wide malaria survey in Mozambique. II. Malaria attributable proportion of fever and establishment of malaria case definition in children across different epidemiological settings , 2009, Malaria Journal.

[47]  M. Alpers,et al.  Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria , 1995, Parasite immunology (Print).

[48]  R. Snow,et al.  Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. , 2005, The Journal of infectious diseases.

[49]  M. Alpers,et al.  Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. , 1996, The American journal of tropical medicine and hygiene.

[50]  Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[51]  M. Schluchter,et al.  Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. , 2005, The American journal of tropical medicine and hygiene.

[52]  V. A. Stewart,et al.  Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya , 2009, PloS one.

[53]  J. K. Moch,et al.  Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Sabchareon,et al.  Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. , 1991, The American journal of tropical medicine and hygiene.

[55]  T. Theander,et al.  Cytophilic antibodies to Plasmodium falciparum Glutamate Rich Protein are associated with malaria protection in an area of holoendemic transmission , 2005, Malaria Journal.

[56]  H. Bujard,et al.  A multifunctional serine protease primes the malaria parasite for red blood cell invasion , 2009, The EMBO journal.

[57]  S. Donachie,et al.  46-53 kilodalton glycoprotein from the surface of Plasmodium falciparum merozoites. , 1989, Molecular and biochemical parasitology.

[58]  É. Braga,et al.  Variant-specific antibodies to merozoite surface protein 2 and clinical expression of Plasmodium falciparum malaria in rural Amazonians. , 2007, The American journal of tropical medicine and hygiene.

[59]  T. Theander,et al.  Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. , 2000, The Journal of infectious diseases.

[60]  D. Conway,et al.  Repeat Sequences in Block 2 of Plasmodium falciparum Merozoite Surface Protein 1 Are Targets of Antibodies Associated with Protection from Malaria , 2003, Infection and Immunity.

[61]  R. Chilengi,et al.  Humoral Responses to Plasmodium falciparum Blood-Stage Antigens and Association with Incidence of Clinical Malaria in Children Living in an Area of Seasonal Malaria Transmission in Burkina Faso, West Africa , 2007, Infection and Immunity.

[62]  S. Satpathy,et al.  Severe falciparum malaria , 2004, Indian journal of pediatrics.

[63]  A. Tartar,et al.  Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. , 1994, Blood.

[64]  A. Thomas,et al.  The Glutamate-Rich Protein (GLURP) of Plasmodium falciparum Is a Target for Antibody-Dependent Monocyte-Mediated Inhibition of Parasite Growth In Vitro , 1998, Infection and Immunity.

[65]  Nikolaos A Patsopoulos,et al.  Uncertainty in heterogeneity estimates in meta-analyses , 2007, BMJ : British Medical Journal.

[66]  D. Conway,et al.  Analysis of Human Antibodies to Erythrocyte Binding Antigen 175 of Plasmodium falciparum , 2000, Infection and Immunity.

[67]  H. Lipps,et al.  Limited sequence polymorphism in the Plasmodium falciparum merozoite surface protein 3. , 1997, Molecular and biochemical parasitology.

[68]  S. Cousens,et al.  Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria? , 2008, Tropical medicine & international health : TM & IH.

[69]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[70]  K. Marsh,et al.  Immune effector mechanisms in malaria , 2006, Parasite immunology.

[71]  L. Konaté,et al.  Impact of red blood cell polymorphisms on the antibody response to Plasmodium falciparum in Senegal. , 2006, Microbes and infection.

[72]  D. Conway,et al.  Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. , 2007, The Journal of infectious diseases.

[73]  J. Sterne,et al.  Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. , 2001, Journal of clinical epidemiology.

[74]  J. Richards,et al.  The future for blood‐stage vaccines against malaria , 2009, Immunology and cell biology.

[75]  Q. Wang,et al.  A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. , 2008, Vaccine.

[76]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[77]  Christl A. Donnelly,et al.  Immunity to non-cerebral severe malaria is acquired after one or two infections , 1999, Nature Medicine.

[78]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.